Beijing TCRCure Bio-pharma Technology Company established.
Chongqing TCRCure Bio-Pharma Technology Company established.
Beijing TCRCure was awarded BJ Zhongguancun High Tech Enterprise Certificate.

TCR screening platform (TRUST) was developed.
1st TCR was cloned.
Development of CHECK-T platform initiated.

Postdoctoral fellow Workstation established.

1st patient was dosed.
Development of TURBO-T platform initiated.

Guangdong TCRCure Bio-pharm Technology Co. Ltd. established.
Los Angeles GMP production and translation center established.
Chongqing TCRCure was certified for Practicing License of Medical Institution.

1st patient was dosed with CHECK-T product.
1st patient was dosed with second CHECK-T product.
Preclinical development of first CAR-T product initiated.

Guangzhou GMP production and translation center established.
TCRCure GD passed the GMP audit.
TCRCure was awarded as Pioneer Enterprise by the Top 50 Innovative Biotechnology Enterprises in GD-HK-Marco Greater Bay Area.

1st patient was dosed with CAR-T product.
1st patient was dosed with TURBO-T product.

National High Technology Enterprise was awarded 

TC-E202 IND approval.

TCRCure awarded KPMG's “Top 50 Biotechnology Innovators in China.”
TCRCure was awarded "China's Top 100 Innovative Biomedicines" by VBDATA.
TCRCure was awarded "Guangzhou Future Unicorn Innovation Enterprise."
TCRCure was recognized as "2022 Innovative Small and Medium-sized Enterprises."
TCRCure was awarded the "5th the Greater Bay Area Top 50 Biotechnology Innovation Enterprises."

TC-N201 IND approval.
TCRCure’s clinical results published at the European Society of Medical Oncology Annual Meeting (ESMO).
TCRCure’s clinical result published at the 37th Annual Meeting of the Society for Cancer Immunotherapy (SITC).

TCRcure’s research and development service was selected as "2022 Guangdong Province High-tech Products."
TCRCure was awarded The Most Growth of New Cell Therapy Enterprises Top10 of Chinese Medical Rankings ·2023 Cell and Gene Therapy Industry Prospect Rankings.
TCRCure was awarded the Guangzhou Future Unicorn Innovation Enterprise.

TCRCure’s clinical results published at the 2023 ASCO Annual Meeting.

TCRCure was accredited as 'Specialized in Special New' Small and Medium-sized Enterprises (SMEs).
TCRCure was awarded the Guangzhou Future Unicorn Innovation Enterprise.
TCRCure ranked on the Hurun Global Cheetahs Index 2024.
TCRCure was awarded the "7th the Greater Bay Area Top 50 Biotechnology Innovation Enterprises."

TCRCure has signed a cooperation agreement with the Office for Attracting Selected Enterprises (OASES) of the HKSAR.